Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug RepurposingShort communication Published on 2020-12-012022-10-05 Journal: Journal of pharmaceutical sciences [Category] SARS, 신약개발, 치료제, [키워드] ACE2 receptor Antiviral antiviral activity cellular Combination Concentration COVID-19 described determine develop development doses drug Efficacy exposure geometric host cell Human human lung humans IC50 Importins in vitro Inhaled inhibiting Ivermectin Kinetics less lung lung tissue mechanism Minimal physiologically-based pharmacokinetic model Model nuclei oral pharmacokinetic Pharmacokinetic/pharmacodynamic (PK/PD) modeling pharmacokinetics Pharmacometrics Physiologically based pharmacokinetic modeling plasma plasma concentration profile reached reported repurposing SARS-CoV-2 shown subunit therapeutic potential were used [DOI] 10.1016/j.xphs.2020.08.024 [Article Type] Short communication